Item 5.07 Submission of Matters to a Vote of Security Holders

On December 9, 2022, Greenwich LifeSciences, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). A total of 9,755,196 shares of common stock, constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on October 19, 2022 are as follows:

Proposal 1. All of the five (5) nominees for director were elected to serve until the 2023 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death. The result of the votes to elect the five (5) directors was as follows:





Directors                       For          Against       Abstain       Broker Non Vote
David McWilliams              8,452,115             0       484,781               818,300
Snehal S. Patel               8,567,603             0       369,293               818,300
Eric Rothe                    8,526,477             0       410,419               818,300
F. Joseph Daugherty, M.D.     8,532,215             0       404,681               818,300
Kenneth Hallock               8,561,615             0       375,281               818,300

Proposal 2. The appointment of Malone Bailey, LLP as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2022 was ratified and approved by the stockholders by the votes set forth in the table below:





    For         Against      Abstain       Broker Non Vote
  9,733,708       15,043        6,444                     0

-2-

© Edgar Online, source Glimpses